Company / Cost of Revenue
BioXcel Therapeutics, Inc. Cost of Revenue History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$164.0K
FY2025
5-year range
$20.0K / $1.3M
FY2022-FY2025
Trend
-87.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $20,000 to $164,000 over the past 2 years.
Based on SEC 10-K filings.
$164,000 in FY2025 with a 3-year CAGR of +101.7%.
Increased from $20,000 to $164,000 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +101.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +101.7%, indicating consistent growth.
- In FY2025, cost of revenue decreased 87.0% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $164.0K | -87.0% |
| FY2024 | $1.3M | +6200.0% |
| FY2023 | $20.0K | +0.0% |
| FY2022 | $20.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026